Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

Authors: Naomi B. Haas, Judith Manola, Robert G. Uzzo, Keith T. Flaherty, Christopher G. Wood, Christopher J. Kane, Michael A.S. Jewett, Janice P. Dutcher, Michael B. Atkins, Michael Pins, George Wilding, David Cella, Lynne I. Wagner, Surena F. Matin, Timothy M. Kuzel, Wade J. Sexton, Yu-Ning Wong, Toni K. Choueiri, Роберто Пили, Igor Puzanov, Manish Kohli, Walter M. Stadler, Michael A. Carducci, Robert Coomes, Robert S. DiPaola - The Lancet 2016 cited by 638